Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1997, for Regeneron Pharmaceuticals, Inc. The company is a biotechnology firm focused on the discovery, development, and commercialization of pharmaceutical products. As of the reporting date, Regeneron has not generated revenue from the commercial sale of products and relies on collaboration agreements, research progress payments, and investment income to fund operations. The company maintains a cumulative deficit of approximately $169.1 million since its inception in 1988.
Key Financial Metrics
| Metric | Q3 1997 | Q3 1996 | 9 Months 1997 | 9 Months 1996 |
|---|---|---|---|---|
| Total Revenue | $8.9 million | $6.2 million | $21.7 million | $17.6 million |
| Net Loss | ($1.9 million) | ($8.9 million) | ($12.1 million) | ($24.3 million) |
| Net Loss Per Share | ($0.06) | ($0.35) | ($0.43) | ($1.01) |
| Cash & Cash Equivalents | $40.3 million | $34.5 million (Dec '96) | End of Period: $40.3 million | |
| Marketable Securities | $86.4 million (Total) | $62.6 million (Total) | End of Period: $86.4 million | |
| Total Assets | $164.7 million | $137.6 million (Dec '96) | End of Period: $164.7 million | |
| Total Liabilities | $26.5 million | $30.7 million (Dec '96) | End of Period: $26.5 million |
Liquidity: The company held $126.6 million in cash, cash equivalents, and marketable securities as of September 30, 1997. Net cash used in operating activities for the nine months ended September 30, 1997, was $9.2 million, compared to $20.2 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 43% in Q3 1997 compared to Q3 1996, driven by a $2.5 million research progress payment from The Procter & Gamble Company (P&G) and increased contract manufacturing revenue from Merck & Co., Inc.
- Reduced Losses: Net loss improved significantly, decreasing from $8.9 million in Q3 1996 to $1.9 million in Q3 1997. This was primarily due to a reduction in the loss recognized from the Amgen-Regeneron Partners joint venture (down from $4.1 million to $0.7 million) and lower R&D expenses.
- Collaboration Expansion: In September 1997, the company amended its agreement with P&G to include the development of AXOKINE for obesity associated with Type II diabetes, securing up to $15.0 million in additional funding.
- Investment Income: Investment income rose to $1.8 million in Q3 1997 from $1.4 million in Q3 1996, attributed to higher interest-bearing investments following equity placements with P&G.
Outlook, Risks, and Management Commentary
Management Commentary: Management expects to incur substantial funding requirements for R&D, clinical testing, and manufacturing facility validation. The company believes existing capital resources will meet operating needs for at least the next several years. However, future capital contributions to the Amgen-Regeneron Partners joint venture are anticipated to increase.
Risks and Contingencies:
- Clinical Trial Risks: The Phase III trial of BDNF for ALS failed to meet primary endpoints. Future subcutaneous studies are based on retrospective analysis, and there is no assurance of success. Similarly, NT-3 development for enteric neuropathies faces significant clinical trial risks.
- Collaboration Dependence: The company relies heavily on funding from partners (P&G, Amgen, Merck, Sumitomo). Termination of these agreements could materially adversely affect operations.
- Intellectual Property: The company is involved in two interference proceedings regarding CNTF patents with Synergen, Inc. (acquired by Amgen), which could impact future commercialization rights.
- Financing: The company has no established banking arrangements for short-term financing and may need to issue additional securities or secure new collaborations to fund future operations.
Key Facts for Investor Verification
- Revenue Source: Verify the sustainability of revenue streams, as the company has no commercial product sales and relies on milestone payments and research reimbursements.
- BDNF Clinical Status: Confirm the status and design of planned subcutaneous BDNF trials for ALS, given the failure of the previous Phase III intrathecal trial.
- P&G Agreement Terms: Review the specific milestones required to unlock the remaining $12.5 million of the $15.0 million additional funding from P&G for AXOKINE.
- Amgen-Regeneron Partners: Monitor the capital contribution requirements for the joint venture, which are expected to increase in future years.
- Patent Litigation: Track the outcome of the interference proceedings with Synergen/Amgen regarding CNTF patents.